OncoSec
Biotechnology ResearchCalifornia, United States11-50 Employees
OncoSec is a small biotechnology company based in San Diego, California, focused on immuno-oncology. It pursues a proprietary approach that transfers DNA into tumors to stimulate the body's immune system, with the goal of delivering interleukin-12 directly within tumors for targeted and sustained immune activity. Clinical data have shown local tumor effects and evidence of systemic anti-tumor responses in several studies, including Phase 2 trials in anti-PD-1–refractory metastatic melanoma and in metastatic triple-negative breast cancer. The company intends to extend this DNA-encoded immunotherapy framework to additional cancer indications and other immunologic genes. As a player in the biotechnology research industry, OncoSec focuses on developing immunotherapies that could offer long-term benefits for patients with limited treatment options. It has received FDA Orphan Drug and Fast-Track designations for its TAVO program in metastatic melanoma, reflecting its regulatory pathway considerations. The organization pursues broader development of DNA-encoded therapeutic candidates to address a wider range of cancers.
1-888-653-2347 
support@leadiq.com 
